Soueidan S A, Dalakas M C
Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 28092.
Neurology. 1993 May;43(5):876-9. doi: 10.1212/wnl.43.5.876.
We report the treatment of four patients with inclusion-body myositis (IBM) and severe slowly progressive weakness using high-dose intravenous immunoglobulin (IVIg). After two monthly infusions, the strength of the proximal and less atrophic muscle groups improved or normalized in three of the four patients. The improvement lasted from 2 to 4 months. Intravenous immunoglobulin is the first treatment modality to improve the strength of some muscles in patients with this disabling inflammatory myopathy. In view of the high cost of IVIg, the unexpected but encouraging results from this pilot study warrant a controlled trial.
我们报告了使用大剂量静脉注射免疫球蛋白（IVIg）治疗4例包涵体肌炎（IBM）且伴有严重缓慢进行性肌无力的患者。在每月进行两次输注后，4例患者中有3例近端及萎缩较轻的肌群力量得到改善或恢复正常。改善持续了2至4个月。静脉注射免疫球蛋白是改善这种致残性炎性肌病患者某些肌肉力量的首个治疗方式。鉴于IVIg成本高昂，这项初步研究取得的意外但令人鼓舞的结果值得进行对照试验。
